Galapagos NV

Biotechnology • Healthcare • Mechelen, Belgium • GLPGF (PNK)

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Stock Performance (90 Days)

Data through Dec 24, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Galapagos: Pivoting From Clinical Risk To Strategic Capital Allocation (NASDAQ:GLPG) - Seeking Alpha

Seeking Alpha • Dec 22

Galapagos stock holds steady as Raymond James maintains Market Perform rating - Investing.com

Investing.com • Dec 19

Biotech company Galapagos to phase out cell therapy operations, putting 365 jobs at risk - belganewsagency.eu

belganewsagency.eu • Oct 21

GLPG Crosses Above Average Analyst Target - Nasdaq

Nasdaq • Dec 12

Aug Catalysts: Is Galapagos NV (Common Stock) (GXEA) stock a top hedge fund pick - July 2025 Review & Real-Time Buy Signal Notifications - moha.gov.vn

moha.gov.vn • Dec 29

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has GALAPAGOS NV had layoffs?

No layoff events have been recorded for GALAPAGOS NV in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does GALAPAGOS NV have?

GALAPAGOS NV has approximately 704 employees.

What industry is GALAPAGOS NV in?

GALAPAGOS NV operates in the Biotechnology industry, within the Healthcare sector.

Is GALAPAGOS NV a publicly traded company?

Yes, GALAPAGOS NV is publicly traded under the ticker symbol GLPGF on the PNK. The company has a market capitalization of approximately $2.12 billion.

Where is GALAPAGOS NV headquartered?

GALAPAGOS NV is headquartered in Mechelen, Belgium.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.